[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544525":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":25,"responsibleParty":80,"collaborators":7,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":7,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":90,"phases":7,"briefSummary":91,"conditions":92,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"TransThera Sciences (Nanjing), Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Tinengotinib","Subjects on this rollover study may continue to receive tinengotinib at the dose that they were previously receiving on the TransThera parent study. Dose may be decreased by one dose level from the previously-received dose upon study entry, based on physician discretion.",[14],"TT-00420",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Katie Hennessy, MS","CONTACT","267-627-0150","katie_hennessy@transtherabio.com",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":24},"Hui Wang, MS","301-859-0848","wang_hui@transtherabio.com",[26,40,50,60,70],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":7},"University of Chicago Medical Center","AVAILABLE","Chicago","Illinois","60637","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-87.65005,41.85003,{"lat":38,"lon":37},{"facility":41,"status":28,"city":42,"state":43,"zip":44,"country":32,"countryCode":33,"cosmosGeoPoint":45,"geoPoint":49,"contacts":7},"Roswell Park Comprehensive Cancer Center","Buffalo","New York","14203",{"type":35,"coordinates":46},[47,48],-78.87837,42.88645,{"lat":48,"lon":47},{"facility":51,"status":28,"city":52,"state":53,"zip":54,"country":32,"countryCode":33,"cosmosGeoPoint":55,"geoPoint":59,"contacts":7},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":35,"coordinates":56},[57,58],-86.78444,36.16589,{"lat":58,"lon":57},{"facility":61,"status":28,"city":62,"state":63,"zip":64,"country":32,"countryCode":33,"cosmosGeoPoint":65,"geoPoint":69,"contacts":7},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":35,"coordinates":66},[67,68],-95.36327,29.76328,{"lat":68,"lon":67},{"facility":71,"status":28,"city":72,"state":73,"zip":74,"country":32,"countryCode":33,"cosmosGeoPoint":75,"geoPoint":79,"contacts":7},"UW Carbone Cancer Center","Madison","Wisconsin","53705",{"type":35,"coordinates":76},[77,78],-89.40123,43.07305,{"lat":78,"lon":77},{"type":81,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100544525","rollover-study-to-provide-continued-access-to-tt-00420-tinengotinib-for-subjects-with-advanced-solid-tumors-100544525",false,"NCT06370013","Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors","An Open Label, Multicenter Rollover Study for Continued Characterization of Safety and Tolerability of TT-00420 (Tinengotinib) Tablet Monotherapy in Adult Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Subject is currently enrolled in a pre-defined TransThera-sponsored parent study and is receiving tinengotinib as a single agent.\n2. Subject is currently deriving clinical benefit from the study treatment, as determined by the investigator.\n\nExclusion Criteria:\n\n1. Subject has been permanently discontinued from tinengotinib in the parent protocol for any reason other than enrollment in the Rollover study\n2. Subject does not meet the criteria specified in the parent protocol for continued treatment on study.","ALL","EXPANDED_ACCESS","This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors",[93,94],"Advanced Solid Tumors","Cholangiocarcinoma","2024-04-16",{"date":97,"type":98},"2024-04-17","ACTUAL",{"name":5,"class":6},5]